DUAL MONOCLONAL ANTIBODY THERAPIES |
Previously untreated, unresectable or metastatic melanoma |
NCT02905266 |
Nivolumab + ipilimumab |
Arm A: nivolumab and ipilimumab concomitant administration followed by nivolumab monotherapy Arm B: nivolumab and ipilimumab sequential administration followed by nivolumab monotherapy |
Anti-PD-1 + anti-CTLA-4 |
Active, not recruiting |
Complete resection of stage IIIB/C/D or stage IV melanoma |
NCT03068455 (CheckMate 915) |
Nivolumab + ipilimumab |
Arm A: nivolumab + ipilimumab Arm B: nivolumab |
Anti-PD-1 + anti-CTLA-4 |
Active, not recruiting |
Previously untreated, unresectable or metastatic melanoma |
NCT02714218 |
Nivolumab + ipilimumab |
Arm A: nivolumab 3 mg/kg IV + ipilimumab 1 mg/kg IV Arm B: ipilimumab 3 mg/kg IV + nivolumab 1 mg/kg IV Arm C: nivolumab 6 mg/kg IV + ipilimumab 1 mg/kg |
Anti-PD-1 + anti-CTLA-4 |
Active, not recruiting |
First-line for advanced melanoma |
NCT02599402 (CheckMate 401) |
Nivolumab + ipilimumab |
Arm A: nivolumab + ipilimumab Arm B: nivolumab |
Anti-PD-1 + anti-CTLA-4 |
Active, not recruiting |
Unresectable or metastatic melanoma |
NCT03470922 |
Nivolumab +relatlimab |
Arm A: relatlimab + nivolumab Arm B: nivolumab |
Anti-PD-1 + LAG-3 inhibitor |
Recruiting |
COMBINED MONOCLONAL ANTIBODY AND TYROSINE KINASE INHIBITORS |
Stage III-IV BRAFV600 melanoma |
NCT02224781 |
Ipilimumab and nivolumab + dabrafenib and trametinib |
Arm A: ipilimumab and nivolumab then dabrafenib and trametinib Arm B: dabrafenib and trametinib then ipilimumab and nivolumab |
Anti-CTLA-4 and anti-PD-1 + BRAF inhibitor and MEK inhibitor |
Recruiting |
Previously untreated BRAFV600 mutation-positive patients with metastatic or unresectable locally advanced melanoma |
NCT02908672 |
Atezolizumab + cobimetinib + vemurafenib |
Arm A: atezolizumab + cobimetinib + vemurafenib + vemurafenib placebo Arm B: atezolizumab placebo + cobimetinib + vemurafenib |
Anti-PD-1 + MEK inhibitor + BRAF inhibitor |
Active, not recruiting |
Previously untreated advanced BRAFV600 wild-type melanoma |
NCT03273153 |
Atezolizumab + cobimetinibPembrolizumab |
Arm A: atezolizumab + cobimetinib Arm B: pembrolizumab |
Anti-PD-L1 + MEK inhibitorsAnti-PD-1 |
Recruiting |
MONOCLONAL ANTIBODY THERAPIES COMBINED WITH OTHER AGENTS |
Anti-PD-1 refractory melanoma |
NCT03445533 (ILLUMINATE-301) |
Ipilimumab + IMO-2125 |
Arm A: ipilimumab Arm B: ipilimumab + IMO-2125 |
Anti-CTLA-4 + TLR9 agonist |
Recruiting |
Unresectable or metastatic melanoma |
NCT02752074 (Keynote-252 / ECHO-301) |
Pembrolizumab + epacadostat |
Arm A: pembrolizumab + epacadostat Arm B pembrolizumab + placebo |
Anti-PD-1 + IDO1 inhibitor |
Active, not recruiting |
Untreated unresectable stage III or IV melanoma |
NCT00324155 |
Dacarbazine + ipilimumab |
Arm A: dacarbazine + ipilimumab Arm B: dacarbazine + placebo |
Chemotherapy alkylating agent + anti-CTLA-4 |
Completed |
Unresected melanoma |
NCT02263508 (KEYNOTE-034) |
Pembrolizumab + T-Vec |
Arm A: pembrolizumab + talimogene laherparepvec Arm B: pembrolizumab + placebo |
Anti-PD-1 + oncolytic herpes virus |
Active, not recruiting |
Unresectable or metastatic melanoma |
NCT03301636 (NLG2107) |
Pembrolizumab/nivolumab + indoximod |
Arm A: pembrolizumab + indoximiod Arm B: pembrolizumab + placebo Arm C: nivolumab + indoximiod Arm D: nivolumab + placebo |
Anti-PD-1 + IDO inhibitor |
Recruiting |